TNXP

+ Watchlist + Portfolio

Tonix Pharmaceuticals Holding Corp.

Regulated industry Physical products Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $9.23
52-Week Range: $8.69 – $24.67
Market Cap: $152.82M
P/E (TTM): —
EPS (TTM): -13.06
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 0.56
PEG Ratio: —
Return on Equity: -81.82%
Return on Assets: -46.84%
Gross Margin: 83.83%
Operating Margin: -314.05%
Profit Margin: 0.00%
Current Ratio: 6.61
Debt/Equity: 0.01
Total Debt: $1.27M
Free Cash Flow: $-95.76M
Revenue Growth: 577.90%
Earnings Growth: —
Enterprise Value: $-22.14M

TNXP Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$7.77M	$10.09M	$13.11M
Cost of Revenue	$0.00	$4.74M	$7.76M	$6.64M
Gross Profit	$0.00	$3.03M	$2.33M	$6.47M
Research & Development	$81.88M	$86.66M	$39.97M	$44.49M
Selling, General & Admin	$30.21M	$34.75M	$40.10M	$87.68M
Operating Expenses	$112.09M	$121.41M	$77.48M	$129.16M
Operating Income	-$112.09M	-$118.38M	-$75.15M	-$122.69M
EBITDA	-$110.84M	-$114.09M	-$125.38M	-$122.01M
Pretax Income	-$110.22M	-$116.66M	-$130.04M	-$124.02M
Net Income	-$110.22M	-$116.66M	-$130.04M	-$124.02M
Diluted EPS	-65400.00	-14720.25	-176.60	-14.57
Diluted Shares	1786	7925	736339	8.51M

TNXP Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$120.23M	$24.95M	$98.78M	$207.64M
Receivables	$8.04M	$6.10M	$8.65M	$10.32M
Inventory	$0.00	$14.15M	$8.41M	$7.01M
Current Assets	$130.78M	$47.77M	$119.00M	$228.88M
Total Assets	$225.69M	$154.46M	$162.89M	$277.17M
Current Liabilities	$18.18M	$18.88M	$18.31M	$30.84M
Long-Term Debt	—	$6.56M	$4.67M	—
Total Debt	$760.00K	$9.81M	$8.12M	$1.31M
Total Liabilities	$18.51M	$48.93M	$23.33M	$32.02M
Retained Earnings	-$470.04M	-$600.66M	-$730.69M	-$854.72M
Shareholders' Equity	$207.18M	$105.53M	$139.56M	$245.15M
Working Capital	$112.60M	$28.88M	$100.69M	$198.04M

TNXP Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$98.05M	-$102.00M	-$60.92M	-$99.84M
Capital Expenditure	-$48.15M	-$7.89M	-$120.00K	-$3.37M
Free Cash Flow	-$146.20M	-$109.90M	-$61.05M	-$103.21M
Depreciation & Amortisation	$1.25M	$4.29M	$3.42M	$1.93M
Stock-Based Compensation	$10.91M	$9.28M	$4.78M	$6.02M
Investing Cash Flow	-$48.15M	-$29.07M	-$120.00K	-$4.53M
Financing Cash Flow	$87.84M	$36.52M	$134.87M	$214.53M
Share Repurchases	-$47.25M	-$13.96M	$0.00	-$13.76M
Net Change in Cash	-$58.36M	-$94.56M	$73.83M	$110.16M

TNXP Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$2.43M	$2.00M	$3.29M	$5.39M	$6.88M	$13.54M
Cost of Revenue	$943.00K	$3.27M	$1.37M	$1.06M	$1.58M	$703.00K
Gross Profit	$1.49M	-$1.27M	$1.92M	$4.33M	$5.30M	$12.84M
Research & Development	$7.44M	$10.82M	$9.29M	$16.94M	$18.21M	$19.42M
Selling, General & Admin	$10.10M	$16.20M	$25.70M	$35.68M	$28.62M	$35.96M
Operating Expenses	$16.62M	$25.99M	$34.01M	$52.55M	$46.84M	$54.78M
Operating Income	-$15.13M	-$27.26M	-$32.09M	-$48.22M	-$41.54M	-$41.94M
EBITDA	-$14.64M	-$26.78M	-$31.55M	-$46.42M	-$40.98M	-$41.32M
Pretax Income	-$16.83M	-$28.27M	-$32.01M	-$46.91M	-$40.19M	-$40.55M
Net Income	-$16.83M	-$28.27M	-$32.01M	-$46.91M	-$40.19M	-$40.55M
Diluted EPS	-2.84	-3.86	-3.59	-3.98	-2.93	-2.44
Diluted Shares	5.93M	7.33M	8.92M	11.80M	13.71M	16.64M

TNXP Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$131.72M	$125.33M	$190.06M	$207.64M	$185.47M	$176.23M
Receivables	$4.83M	$7.87M	$6.67M	$10.32M	$12.68M	$15.31M
Inventory	$8.14M	$5.99M	$5.73M	$7.01M	$4.64M	$5.68M
Current Assets	$149.57M	$143.53M	$208.07M	$228.88M	$207.17M	$203.43M
Total Assets	$192.87M	$187.36M	$252.44M	$277.17M	$257.91M	$254.09M
Current Liabilities	$12.15M	$19.06M	$21.03M	$30.84M	$29.65M	$30.79M
Total Debt	$563.00K	$492.00K	$425.00K	$1.31M	$1.29M	$1.27M
Total Liabilities	$12.47M	$19.36M	$21.30M	$32.02M	$30.77M	$31.81M
Retained Earnings	-$747.52M	-$775.79M	-$807.80M	-$854.72M	-$894.91M	-$935.46M
Shareholders' Equity	$180.40M	$168.00M	$231.14M	$245.15M	$227.14M	$222.28M
Working Capital	$137.43M	$124.47M	$187.04M	$198.04M	$177.52M	$172.65M

TNXP Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$16.58M	-$14.83M	-$28.78M	-$39.65M	-$42.32M	-$42.24M
Capital Expenditure	-$6.00K	-$2.54M	—	-$1.87M	-$1.69M	-$587.00K
Free Cash Flow	-$16.59M	-$17.37M	-$27.73M	-$41.52M	-$44.01M	-$42.83M
Depreciation & Amortisation	$493.00K	$483.00K	$461.00K	$488.00K	$555.00K	$619.00K
Stock-Based Compensation	$882.00K	$1.42M	$1.92M	$1.79M	$1.97M	$2.26M
Investing Cash Flow	-$6.00K	-$2.54M	-$962.00K	-$1.02M	-$1.69M	-$587.00K
Financing Cash Flow	$49.53M	$10.99M	$94.86M	$59.14M	$20.20M	$33.51M
Share Repurchases	-$3.05M	-$2.90M	$0.00	-$7.81M	$0.00	$0.00
Net Change in Cash	$32.95M	-$6.38M	$65.12M	$18.47M	-$23.80M	-$9.32M

Market Snapshot

About

Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company developing therapeutics to treat pain, neurologic, psychiatric, and immunologic conditions. The company has a diverse pipeline including product candidates for PTSD, fibromyalgia, Long COVID, and infectious diseases. Tonix also develops vaccines and immunotherapies using proprietary technology platforms.